TIM-3 restrains anti-tumour immunity by regulating inflammasome activation-Reference-Cited by-同舟云学术

TIM-3 restrains anti-tumour immunity by regulating inflammasome activation

Published:2021-06-09 Issue:7865 Volume:595 Page:101-106
ISSN:0028-0836
Container-title:Nature
language:en
Short-container-title:Nature

Author:

Dixon Karen O.^ORCID,Tabaka Marcin,Schramm Markus A.^ORCID,Xiao Sheng,Tang Ruihan,Dionne Danielle,Anderson Ana. C.^ORCID,Rozenblatt-Rosen Orit^ORCID,Regev Aviv^ORCID,Kuchroo Vijay K.^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Multidisciplinary

Link

http://www.nature.com/articles/s41586-021-03626-9.pdf

Reference54 articles.

1. Monney, L. et al. Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease. Nature 415, 536–541 (2002).

2. Sakuishi, K. et al. Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J. Exp. Med. 207, 2187–2194 (2010).

3. Jin, H. T. et al. Cooperation of Tim-3 and PD-1 in CD8 T-cell exhaustion during chronic viral infection. Proc. Natl Acad. Sci. USA 107, 14733–14738 (2010).

4. Rangachari, M. et al. Bat3 promotes T cell responses and autoimmunity by repressing Tim-3-mediated cell death and exhaustion. Nat. Med. 18, 1394–1400 (2012).

5. da Silva, I. P. et al. Reversal of NK-cell exhaustion in advanced melanoma by Tim-3 blockade. Cancer Immunol. Res. 2, 410–422 (2014).

Cited by 220 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Integrated bioinformatic analysis and experimental validation for exploring the key immune checkpoint of COPD;Gene;2024-11

2. Phenotypic and spatial heterogeneity of CD8+ tumour infiltrating lymphocytes;Molecular Cancer;2024-09-09

3. TIM-3 on myeloid cells promotes pulmonary inflammation through increased production of galectin-3;Communications Biology;2024-09-05

4. High infiltration of immune cells with lower immune activity mediated the heterogeneity of gastric adenocarcinoma and promoted metastasis;Heliyon;2024-09

5. TIGIT: Will it be the next star therapeutic target like PD-1 in hematological malignancies?;Critical Reviews in Oncology/Hematology;2024-09